The Short-term Effect of Triple Therapy for Diabetic Macular Edema With Vitreomacular Traction

ABSTRACT

PURPOSE: To evaluate the short-term effect and safety of a triple therapy on diabetic macular edema (DME) with vitreomacular traction. METHODS: Twenty four eyes from 24 subjects, diagnosed with DME with vitreomacular traction, were subjected to vitrectomy. Intravitreal triamcinolone acetonide injection and macular laser photocoagulation were conducted sequentially at one and 14 days after vitrectomy. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded before surgery and at three and six months after triple therapy. RESULTS: The mean (+/-standard deviation [SD]) logarithm of the minimum angle of resolution BCVAs before, three, and six months after the triple therapy were 0.77+/-0.38, 0.48+/-0.27, and 0.47+/-0.36, respectively. The mean (+/-SD) CMTs before, three, and six months after the triple therapy were 407.9+/-127.1 micrometer, 272.4+/-104.6 micrometer, and 263.5+/-131.2 micrometer, respectively. The changes in BCVA at three and six months from treatment were statistically significant. Macular thickness decreased significantly at 3 and 6 months postoperatively. CONCLUSIONS: Triple therapy is a good therapeutic option for diabetic macular edema with vitreomacular traction to improve visual acuity and macular thickness.